Vascular Reconditioning Inc. (``VRI'') to Present at Medtech Insight and Windhover Information's ``In3 Medical Device Summit'' Conference, June 21-23, 2006, in San Francisco, CA.

SAN FRANCISCO -- Vascular Reconditioning Inc. (www.lightsci.com) has announced that it will be presenting on Thursday, June 22, at 11:20 a.m. PT at Medtech Insight and Windhover Information's "In3 Medical Device Summit" Conference, June 21-23, 2006, at The Palace Hotel in San Francisco, CA.

VRI, recently featured in Cardiovascular Innovations ("Clinic imminent for Vascular Reconditioning"), is developing a drug/device combination product for two of the most important unmet medical needs in a $15 billion interventional endovascular therapy market: (1) prevention of restenosis following intervention in the superficial femoral artery in patients with Peripheral Artery Disease (PAD); and, (2) stabilization of Vulnerable Plaque (VP) in patients with coronary artery disease at risk from acute coronary syndromes.

PAD of the lower limbs is a commonly unrecognized manifestation of systemic atherosclerosis. At present, less than 25% of the approximately 15 million U.S. patients with PAD are diagnosed and treated. A substantial increase in the incidence and diagnosis of PAD is predicted, in part due to increasing awareness of PAD among primary care physicians "leading to increased diagnosis and increasing referrals for intervention, especially using an endovascular approach, to restore blood flow, improve claudication, restore mobility and preserve quality of life," said Nick Yeo, President and CEO of VRI.

VP is an area of unstable atherosclerosis in a major coronary artery that may rupture or erode, leading to sudden clotting and blockage -- and heart attack. Even 10 years ago, medicine conceived of atherosclerosis as a slowly evolving process of lipid deposition causing narrowing of the arteries, leading ultimately to heart attack and death. Today, it is known that culprit atherosclerotic lesions that cause heart attack or sudden cardiac death arise from VP typically present in arterial locations that are neither significantly narrowed nor evident on routine coronary angiography.

Vascular Reconditioning is comprised of: (1) LS11, a proprietary water-soluble, exceptionally photoreactive drug, administered via intravenous or intraarterial delivery, that has affinity for certain pathologic elements present within atherosclerotic lesions and at sites of endovascular injury caused during procedures such as balloon angioplasty; and, (2) a single-use endovascular catheter generating light from a light-emitting diode (LED) array mounted in the distal tip that photo-activates LS11 within the vascular target.

"The combination of the self-localizing photoreactive drug LS11 and VRI's unique endovascular LED technology provides the basis for a regional endovascular procedure with potential to add a new dimension to vascular intervention in atherosclerotic disease," added Nick Yeo. "We believe our approach mitigates development risk due to the ongoing clinical oncology experience with LS11 and Japan's approval of this photoreactive drug for cancer treatment, with commercialization by Meiji Seika as Laserphyrin(R) in 2004."

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. The In3 Medical Device Summit (www.meddevicesummit.com) is Medtech Insight's 21st investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.